GENEART AG Combines Net Sales Growth with Strong Earnings in the 1st Half- year of 2008
SOURCE:
Geneart AG
2008-08-13 00:07:00
REGENSBURG, GERMANY–(EMWNews – August 13, 2008) –
- Net sales increase by 43 % to a total of EUR 7.9M - GENEART confirms the prognoses for 2008 - GENEART has expanded its leading position in the gene synthesis market - The collaborations with QIAGEN and Boehringer Ingelheim strengthen the GENEART position as a leading provider for the pharmaceutical and biotechnology industries
Regensburg, August 13, 2008 – GENEART AG, the global leader in gene
synthesis and specialist in the field of Synthetic Biology, is
operating in a strong running market environment with its gene
synthesis core business. The demand for optimized synthetic genes in
research as well as in the pharmaceutical and biotechnology
industries grows steadily. Supported by the market development, the
GENEART AG was again able to significantly increase its net sales and
operating result (EBIT) in the 1st half of 2008 while expanding its
leading market position.
In the 1st half of 2008, the net sales increased by 43 % to a total
of EUR 7.9M (prior year: EUR 5.5M). The total revenue increased to
EUR 8.3M (prior year: EUR 7.0M). The operating result (EBIT) in the
first six month of 2008 was EUR 0.9M and higher than the EBIT of the
1st half year of 2007 with EUR 0.8M. The net sales-based EBIT margin
for the 1st half of 2008 was 11.4 % (EBIT margin for the 1st half of
2007: 14.2 %). The net profit for the period was EUR 0.7M. The net
profit for the same period of 2007 was EUR 0.5M according to IFRS
accounting standards.
During the 2nd Quarter 2008 GENEART achieved net sales of EUR 4.0M.
GENEART was able to increase net sales by 29 % compared to the 2nd
Quarter 2007 with net sales of EUR 3.1M. The EBIT of EUR 0.4M and the
earnings before taxes (EBT) of EUR 0.5M equaled those of the previous
year.
Christian Ehl, CEO/CFO of GENEART AG comments: “With the successful
1st half of 2008 we are on the right track to meeting our prognoses
for the entire year. The large NIH order has greatly influenced the
net sales and earnings in 2007. However, fast growing business
activities and NIH follow-up orders have by and large already
compensated for the completion of the first large NIH order by the
end of 2007. Through the rest of 2008, we expect to continue
profiting from the currently completed preparations of our capacity
increases.”
Professor Ralf Wagner, CEO/CSO of GENEART AG points out: “We are
ready for the next step. At the end of 2007 we had increased our
capacities to 2M base pairs per month. That means our capacities more
than quadrupled in the past two years. For the next quantum leap we
are now advancing our technology, the software and also our
proprietary processes to entirely new levels. Therefore we
systematically invest in new automation and process technologies,
thus creating the prerequisites for further capacity expansions to 5M
base pairs per month by the end of 2009 and to 10M by the end of
2010.”
In the 2nd Quarter 2008, GENEART kept underpinning its excellent
position in the gene synthesis market through new projects and orders
and once again through the collaboration with the NCI (US National
Cancer Institute, part of the US American National Institutes of
Health NIH). In 2007, GENEART had successfully fulfilled the largest
and most voluminous single gene synthesis order worldwide. Now, after
the close of the reporting period, GENEART was awarded the second NIH
follow-up order in the amount of USD 0.8M. Overall, NIH have placed
orders with GENEART totaling USD 2.7M in 2008 as part of the
“Mammalian Gene Collection” program.
Through technology and distribution collaborations with QIAGEN and
Boehringer Ingelheim GENEART was also able to further strengthen its
position as a leading provider for the pharmaceutical and
biotechnology industries.
The strategic partnership with QIAGEN to distribute synthetic
standard mammalian genes ideally complements GENEART’s core business
to synthesize genes according to individual customer requests. These
standardized genes are optimized and synthesized by GENEART and
distributed via QIAGEN’s GeneGlobe internet portal.
The partners Boehringer Ingelheim and GENEART collaborate in the
areas of design and production services for DNA-based therapeutics
and vaccines. As a result, the partners offer customers unique and
comprehensive system solutions for their projects in this fast
growing market segment. The transfer of the Boehringer Ingelheim
technology for production and purification to GENEART guarantees
customers the consistent quality of delivered biopharmaceutical
agents throughout the entire development process. This provides
customers with the benefit of avoiding unnecessary and expensive
delays in the development of DNA-based therapeutics and vaccines
caused by repeated studies to prove consistent agent quality. In this
collaboration GENEART designs and produces the biopharmaceuticals for
research and preclinical experiments and Boehringer Ingelheim for
clinical studies and the global market.
The GENEART AG in the 1st Half of 2008:
in Million EUR 1st Half of 2008 1st Half of 2007 Net Sales 7.9 5.5 Total Revenue 8.3 7.0 Earnings before Taxes (EBT) 1.1 1.0 EBIT 0.9 0.8 EBIT Margin Based on Net Sales 11.4 % 14.2 %
For further inquiries, please contact:
Bernd Merkl GENEART AG Josef-Engert-Str. 11 93053 Regensburg Germany Phone: +49-(0)941-942 76-638 Fax: +49-(0)941-942 76-711 [email protected] www.geneart.com Frank Ostermair Better Orange IR & HV AG Haidelweg 48 81241 Munich Germany Phone: +49-(0)89-8896906-10 Fax: +49-(0)89-8896906-66 [email protected] www.better-orange.de
Legal Information
This document may contain estimates, prognoses and opinions about
company plans and objectives, products or services, future results,
opinions about these results or opinions leading up to these results.
All these projections into the future are subject to risk,
uncertainty and unforeseeable change outside the control of the
GENEART Group. Many factors may lead to actual results, which
considerably deviate from the given projections for these results.
About GENEART AG
In 2000, GENEART entered the gene synthesis market and has since
become the global market leader. Today, the company is one of the
leading specialists in the Synthetic Biology field. Experts at
GENEART provide key technologies for the development and production
of new therapeutics and vaccines. Customers also take advantage of
GENEART services to customize enzyme attributes, such as the
attributes of enzymes used as detergent additives, and to construct
bacteria, which produce complex biopolymers or break down polymers,
such as synthetics, petroleum components, etc. Our production and
service spectrum spans a wide range, from the production of synthetic
genes according to DIN EN ISO 9001-2000, to the creation of gene
libraries in the combinatorial biology, to the development and
production of DNA-based biologically active substances. The GENEART
AG in Regensburg (Germany) and the subsidiary GENEART Inc. in Toronto
(Canada) employ more than 190 people. Since May 2006, GENEART is
listed on the German Stock Exchange.
http://hugin.info/136633/R/1242818/267381.pdf
Copyright © Hugin AS 2008. All rights reserved.
